Cerebrolysin

Mechanism

A mixture of small brain-derived proteins and amino acids made from pig brain tissue. It mimics the effects of natural nerve growth factors to protect and repair brain cells. Approved in over 40 countries for stroke, TBI, and dementia, but not in the US. Given as an IV or IM injection.

Effects

## Detailed Effects — Cerebrolysin ### Central Nervous System — Neuroprotection [Tier 1-2] - Standardized porcine brain-derived peptide preparation: mixture of low-molecular-weight neuropeptides (<10 kDa, ~75%) and free amino acids (~25%). Contains fragments with BDNF-like, GDNF-like, NGF-like, and CNTF-like activity. - Multimodal neurotrophic mechanism: promotes neuronal survival, stimulates neurogenesis, enhances synaptic plasticity, and reduces neuroinflammation. - Specific molecular effects: upregulates BDNF and NGF expression, activates TrkB and PI3K/Akt survival signaling, inhibits GSK-3beta (relevant to tau phosphorylation in AD), modulates calpain-mediated cell death, reduces oxidative stress via SOD and catalase upregulation. - **Stroke**: CASTA trial (Bornstein et al., Neurology 2018, n=208): improved early neurological recovery (NIHSS) and 90-day functional outcomes (mRS) when given within 24 hours of acute ischemic stroke. CARS trial showed similar benefits. - **Alzheimer's disease**: Meta-analysis of 6 RCTs (Gauthier et al., 2015): statistically significant improvement in global clinical function (CGI) and cognitive performance (ADAS-cog). Effect sizes comparable to cholinesterase inhibitors. - **Traumatic brain injury**: Multiple RCTs and observational studies showing improved cognitive recovery — particularly in moderate TBI. ### Central Nervous System — Cognitive Enhancement [Tier 2-3] - In non-pathological states, Cerebrolysin has been used for cognitive enhancement — proposed mechanism via BDNF upregulation, enhanced synaptic plasticity, and improved neurotransmitter balance. - Approved in 40+ countries for cognitive disorders, stroke, and TBI (NOT FDA-approved in the US). ### Anti-Inflammatory [Tier 2] - Reduces microglial activation and pro-inflammatory cytokine production in neuroinflammatory models. - Attenuates blood-brain barrier disruption after ischemic injury. - Modulates NF-kappaB signaling pathway.

Practitioner Guide

## Practitioner Guide — Cerebrolysin ### Regulatory Status - Approved in 40+ countries (Russia, China, Austria, South Korea, much of Europe, Latin America, Southeast Asia) for stroke, TBI, dementia, and cognitive disorders. - NOT FDA-approved in the US. Available through international pharmacies, some compounding pharmacies, and research peptide suppliers. - Available as pre-filled ampules (1 mL, 5 mL, 10 mL) and vials (30 mL). Each mL contains 215.2 mg of brain-derived peptide mixture. ### Dosing Protocols — Standard Clinical Use **Basic Cognitive Enhancement / Maintenance Protocol** - 5 mL IM daily x 10-20 consecutive days. - Each 5 mL ampule = 1 IM injection. No dilution needed for IM. - Repeat courses every 4-8 weeks. - This is the most common starting protocol for general cognitive optimization. **Advanced Neuroprotection / Stroke Recovery Protocol** - 20-30 mL IV daily x 10-20 consecutive days. - MUST be given IV (not IM) at doses above 10 mL. - Dilute in 100-250 mL normal saline, infuse over 15-30 minutes. - Clinical supervision required for IV administration. - Repeat courses with 4-8 week breaks between courses. - The CASTA and CARS stroke trials used 30 mL/day IV for 10 days initiated within 12-24 hours of acute stroke. **Moderate Cognitive Protocol (Practitioner Favorite)** - 10 mL IV or IM daily x 10 days, then 5 mL IM x 10 days. - Total course: 20 days. Repeat every 6-8 weeks. - Popular among longevity physicians for cognitive optimization in patients 50+. ### Stacking Combinations (Experienced Practitioner Protocols) **Nootropic Stack (Cognitive Maximizer)** - Cerebrolysin 5-10 mL IM daily (provides neurotrophic foundation) - + Semax 600-900 mcg intranasal daily (BDNF + dopamine upregulation) - + Selank 400-600 mcg intranasal daily (anxiolytic + BDNF) - Run for 10-20 day courses. The Cerebrolysin provides deep neurotrophic support while Semax/Selank provide rapid-onset cognitive and mood effects. - This is considered the "gold standard" nootropic peptide stack among experienced practitioners. **Post-TBI / Concussion Recovery Stack** - Cerebrolysin 10-20 mL IV daily x 10-20 days - + BPC-157 500 mcg SC daily (anti-inflammatory, neuroprotective) - + Semax 600 mcg intranasal daily (neuroprotection, BDNF) - + NAD+ IV 250-500 mg 2x/week (mitochondrial support) **Alzheimer's / Cognitive Decline Protocol** - Cerebrolysin 30 mL IV daily x 20 days, repeat every 4-6 weeks - + Dihexa 10-20 mg oral daily (HGF/c-Met synaptogenesis) - + Lion's Mane 1-2 g daily (NGF support) - + Omega-3 (2-4 g EPA/DHA daily) ### Cycling Protocol - Standard: 10-20 days ON, 4-8 weeks OFF. - Acute stroke/TBI: 20 days ON, 4 weeks OFF, repeat 2-3 courses. - Maintenance (cognitive optimization): 10-day course every 2-3 months. - No tolerance or tachyphylaxis reported with standard cycling. ### Supplement Synergies - **Lion's Mane mushroom (1-2 g/day)**: NGF upregulation synergizes with Cerebrolysin's BDNF effects. - **Omega-3 fatty acids (2-4 g EPA/DHA)**: Support neuronal membrane integrity and reduce neuroinflammation. - **Magnesium L-threonate (2 g/day)**: Crosses BBB, supports synaptic plasticity. - **Phosphatidylserine (300 mg/day)**: Supports neuronal membrane function. - **CoQ10 / Ubiquinol (200-400 mg/day)**: Mitochondrial support for neurons. ### Storage & Handling - Ampules/vials: Store at room temperature (up to 25°C). Protect from light. Do NOT freeze. - Amber glass ampules — once opened, use immediately. Do not store opened ampules. - Diluted IV solution: use immediately. Do not store. ### Key Cautions - **Porcine origin**: Contraindicated in patients with pork allergy or religious/dietary restrictions. - **Epilepsy**: Contraindicated — may lower seizure threshold. - **Pregnancy/breastfeeding**: Contraindicated — no safety data. - **Renal impairment**: Use with caution, may need dose reduction. - **Injection site**: IM injections of 5 mL are well-tolerated. Some patients report mild soreness. - **IV infusion**: Infuse slowly. Rapid infusion can cause fever, flushing, dizziness.

Dosing Protocols

Contraindications & Cautions

• hard stop — Epilepsy or seizure disorder
  Cerebrolysin may lower the seizure threshold. In patients with epilepsy or history of seizures, it can precipitate breakthrough seizures even in patients on adequate anticonvulsant therapy. This is a labeled contraindication.
  Action: Do not use in patients with epilepsy or history of seizures. This is a contraindication per product labeling.
• hard stop — Pregnancy
  No adequate human safety data during pregnancy. Neurotrophic peptide mixture could affect fetal neurodevelopment in unpredictable ways.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Allergy to porcine (pig) products
  Cerebrolysin is derived from porcine brain tissue. Patients with known allergy or hypersensitivity to porcine proteins may experience anaphylaxis or severe allergic reactions.
  Action: Do not use in patients with known porcine allergy. Skin test may be considered if allergy status is uncertain.
• hard stop — Status epilepticus
  Cerebrolysin is absolutely contraindicated during status epilepticus due to seizure threshold-lowering effects.
  Action: Do not use. This is an absolute contraindication.
• hard stop — Under 18 years of age
  Neuropeptide preparation. Not for unsupervised pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Severe renal failure
  Cerebrolysin is a porcine brain-derived peptide preparation. Severe renal impairment may impair clearance of peptide components, leading to accumulation and increased risk of adverse effects.
  Action: Requires nephrologist evaluation. Dose adjustment may be necessary. Monitor renal function during use.

Evidence

• Cerebrolysin in acute ischemic stroke (CARS): a randomized, double-blind, placebo-controlled trial

  Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Homberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D (2018) — Neurology

  Cerebrolysin (porcine brain-derived neurotrophic peptide mixture) showed improvements in early neurological recovery and functional outcomes at 90 days in acute ischemic stroke patients when administered within 24 hours of onset. NIHSS and mRS scores improved vs placebo. The multimodal neurotrophic mechanism includes BDNF-like and CNTF-like activities.

  moderate

• Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

  Gauthier S, Bhatt D, Engeli S, Muresanu DF, Alvarez XA (2015) — Dementia and Geriatric Cognitive Disorders — PMID: 26088186

  Meta-analysis of six RCTs showed cerebrolysin produced statistically significant improvement in global clinical function (CGI) and cognitive performance (ADAS-cog) in mild-to-moderate Alzheimer's disease patients. Effect sizes were comparable to approved cholinesterase inhibitors. Well-tolerated with adverse event rates similar to placebo.

  moderate

Stacks featuring this peptide

Research Summary

## Research Summary — Cerebrolysin ### Tier 1: Randomized Controlled Trials - **CASTA Trial (Bornstein et al., Neurology 2018, n=208)**: Cerebrolysin 30 mL/day IV x 10 days within 24h of acute ischemic stroke. Improved NIHSS and mRS at 90 days vs placebo. Positive but modest effect sizes. - **CARS Trial (Muresanu et al., J Neurol Sci 2020)**: Confirmatory stroke trial — similar positive results for early neurological recovery. - **Multiple AD RCTs (6 trials pooled in Gauthier meta-analysis)**: Cerebrolysin 30 mL/day IV x 20 days improved ADAS-cog and CGI in mild-to-moderate Alzheimer's. Effect sizes comparable to donepezil/rivastigmine. - **TBI RCTs (multiple)**: Chen et al., 2013 (n=120): Cerebrolysin improved cognitive recovery post-moderate TBI. CAPTAIN trial design published for further study. - **ECOMPASS Trial (Bornstein et al., 2020)**: Cerebrolysin + alteplase vs alteplase alone in acute stroke — combination showed additional benefit. ### Tier 2: Systematic Reviews & Meta-Analyses - **Gauthier et al., Dement Geriatr Cogn Disord 2015**: Meta-analysis of 6 AD RCTs — significant cognitive and global function improvement. Well-tolerated. - **Cochrane Review**: Acknowledges some positive data but notes methodological limitations in many trials and calls for larger, higher-quality studies. - Approved in 40+ countries — extensive real-world evidence and post-marketing safety data. ### Tier 3: Case Reports & Practitioner Protocols - Russian, Chinese, and Austrian neurology departments have 30+ years of clinical experience. - Practitioners consistently report: improved verbal fluency, memory consolidation, mental clarity, and reduced brain fog within 5-10 days of starting a course. - The nootropic community considers Cerebrolysin the "gold standard" injectable nootropic — the combination with Semax + Selank is widely regarded as the most effective cognitive enhancement stack available. - Some practitioners report benefits for post-COVID brain fog (anecdotal, no formal trials). ### Gaps - Not FDA-approved in the US — large Phase 3 US trials have not been conducted. - Cochrane review is cautiously positive but calls for more rigorous methodology. - Mechanism is not fully characterized due to the multi-component nature (peptide mixture, not single molecule). - Head-to-head trials vs established AD drugs (donepezil, memantine) are limited. - Long-term safety data (>5 years of continuous use) is limited. ### Active Trials - CAPTAIN trial (TBI) — large international RCT. - Additional stroke trials in China and Eastern Europe. - Studies of Cerebrolysin + SGLT2 inhibitors for diabetic neuropathy. - Post-COVID cognitive impairment studies planned.